Description
Key facts
Cell type:Jurkat,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp deletion Frameshift: 100%,
Disease:Non-Hodgkin Lymphoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CD1C, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD1c also known as CD1c molecule or R7 is a transmembrane glycoprotein with a molecular weight of approximately 43 kDa. It belongs to the CD1 family of glycoproteins which share structural similarity to major histocompatibility complex (MHC) proteins. CD1c presents lipid and glycolipid antigens to T cells. It is expressed on professional antigen-presenting cells (APCs) like dendritic cells B cells and some monocytes. This expression allows CD1c to function in the immune response by presenting specialized antigens to T cells.
Biological function summary
The function of CD1c involves the presentation of lipid antigens which plays a role in immune recognition. CD1c is a part of a complex that includes β2-microglobulin which stabilizes its structure for antigen presentation. CD1c contributes to the immune surveillance by enabling the recognition of microbial lipid antigens as well as self-lipids by specific T cell subsets. This function supports the body's immune defense by identifying and reacting to potential pathogenic lipids.
Pathways
CD1c is involved in immune response pathways that center around antigen presentation. It interacts with other proteins like CD1a CD1b and CD1d expanding the range of antigens that T cells can recognize. CD1c participates in the lipid antigen presentation pathway influencing both innate and adaptive immunity. The presentation of lipid antigens by CD1c to T cells can trigger signaling pathways that affect both immune activation and resolution.
CD1c is implicated in autoimmune diseases and infections. Its role in antigen presentation makes it a potential factor in autoimmune conditions where immune recognition errors might occur. Additionally CD1c may relate to infectious diseases where mycobacteria or other pathogens present unique lipid antigens. Through its interaction with T cell receptors CD1c can impact how well immune responses are mounted against these challenges making it a notable target for therapeutic development and research.
